Does Removing Fallopian Tubes Prevent Ovarian Cancer?
At a Glance
Yes, removing your fallopian tubes significantly lowers your risk of developing ovarian cancer. Medical experts have discovered that the most common and aggressive ovarian cancers actually begin in the fallopian tubes, making tube removal a highly effective prevention strategy.
Yes, removing your fallopian tubes significantly lowers your risk of developing ovarian cancer. For many years, doctors believed that all ovarian cancers started inside the ovaries themselves. However, breakthrough research has revealed that the most common and aggressive type of ovarian cancer actually begins in the fallopian tubes [1][2].
Because of this discovery, removing the fallopian tubes—a procedure called a salpingectomy—is now recognized as a powerful way to prevent ovarian cancer [3][4]. However, the specific medical recommendations depend heavily on your personal risk level and whether you have a genetic mutation, such as BRCA1 or BRCA2.
The Tubal Origin Hypothesis
The reason fallopian tube removal is so effective comes down to biology. Medical experts now understand that many high-grade serous ovarian carcinomas (the most common and aggressive type) start as microscopic precancerous cells in the fimbriae—the finger-like fringes at the end of the fallopian tubes that sweep eggs from the ovaries [1][5].
These precancerous spots are called STIC lesions (Serous Tubal Intraepithelial Carcinomas) [2][6]. Over time—sometimes taking up to seven years—these abnormal cells can drop from the fallopian tubes onto the ovaries or into the abdominal cavity, where they grow into invasive cancer [2]. By removing the tubes before these cells have a chance to spread, doctors can essentially stop the cancer before it starts [7][8].
(Note: For patients who have already been diagnosed with ovarian cancer, learning about this research can sometimes bring up difficult feelings, such as wishing this procedure had been an option for you in the past. It is completely normal to feel this way, and this information can be a vital tool to help protect your family members.)
Opportunistic Salpingectomy for the General Population
For people at an average risk of ovarian cancer, doctors often recommend an opportunistic salpingectomy [9][10]. This means a surgeon removes the fallopian tubes during another planned pelvic or obstetric surgery, such as a hysterectomy (removal of the uterus), a cesarean section, or pelvic cyst removal [3][11]. It is also highly effective as a method of permanent birth control, often chosen instead of traditional “tube tying” (tubal ligation) [3].
This approach offers major benefits:
- Lower cancer risk: It significantly reduces the chances of developing epithelial ovarian cancer [3][4].
- No forced menopause: Unlike removing the ovaries, taking out only the fallopian tubes does not cause sudden surgical menopause. Your ovaries stay in place and continue to produce hormones normally [12][13].
- Safety and recovery: Studies show that adding fallopian tube removal to another gynecologic surgery is safe, does not increase the risk of surgical complications, and generally does not add to your recovery time [12][14].
Recommendations for High-Risk Individuals
If you have a strong family history of ovarian cancer or carry a genetic mutation like BRCA1 or BRCA2, your risk profile is different. For high-risk individuals, removing only the fallopian tubes is not currently the standard of care [15][16].
Instead, the established medical recommendation is a risk-reducing salpingo-oophorectomy (RRSO), which means removing both the fallopian tubes and the ovaries [15][17]. While many cancers start in the tubes, genetic mutations like BRCA drastically heighten the risk for the ovarian tissue as well, meaning leaving the ovaries behind still leaves you at an unacceptably high risk for cancer developing directly in the ovaries later [15][18]. While taking out the ovaries does cause premature menopause in premenopausal individuals, it provides the necessary, comprehensive protection for those with these mutations [19][18].
Some clinical trials are investigating a two-step approach for high-risk individuals: removing the tubes first to lower immediate risk, and delaying ovary removal until closer to natural menopause to preserve hormones [20][21]. However, this is still considered experimental and is typically only offered within formal research studies [21][22].
Is it a 100% guarantee?
While removing your fallopian tubes dramatically cuts your risk, it is important to know that it does not eliminate the risk entirely [23][8]. A rare type of cancer called primary peritoneal cancer can develop in the lining of the abdomen (the peritoneum). This tissue is biologically very similar to the surface of the ovaries, so cancer can still form there even if the tubes and ovaries are gone [23].
A Note for Families
If you have already been diagnosed with ovarian cancer, sharing this prevention information with your sisters, daughters, and other female relatives is incredibly important. Your diagnosis may classify them as higher risk. The most empowering first step for them is to speak with a genetic counselor or a gynecologic oncologist to map out a prevention strategy tailored to their exact genetics and life stage.
Common questions in this guide
Can you still get ovarian cancer if your fallopian tubes are removed?
Does removing my fallopian tubes cause early menopause?
Should I have my fallopian tubes removed if I have a BRCA mutation?
What is an opportunistic salpingectomy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my family history, do I or my female relatives qualify for genetic testing to determine our true risk of ovarian cancer?
- 2.Does my insurance cover removing my tubes during my upcoming scheduled surgery?
- 3.Given my personal risk profile, should I be considering removal of just my fallopian tubes, or both my tubes and ovaries?
- 4.If I ever need pelvic surgery, like a hysterectomy or a cesarean section, would you perform an opportunistic salpingectomy?
- 5.What are the risks of surgical menopause if I need my ovaries removed, and how would we manage those symptoms?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (23)
- 1
Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation-A nationwide case-control study.
Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A
International journal of cancer 2021; (149(8)):1544-1552 doi:10.1002/ijc.33714.
PMID: 34152012 - 2
High grade serous ovarian carcinomas originate in the fallopian tube.
Labidi-Galy SI, Papp E, Hallberg D, et al.
Nature communications 2017; (8(1)):1093 doi:10.1038/s41467-017-00962-1.
PMID: 29061967 - 3
Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.
Hanley GE, Pearce CL, Talhouk A, et al.
JAMA network open 2022; (5(2)):e2147343 doi:10.1001/jamanetworkopen.2021.47343.
PMID: 35138400 - 4
Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer.
Falconer H, Yin L, Salehi S, Altman D
European journal of cancer (Oxford, England : 1990) 2021; (145()):38-43 doi:10.1016/j.ejca.2020.11.046.
PMID: 33418235 - 5
High-grade serous ovarian and fallopian tube carcinomas with similar clinicopathological characteristics might originate from serous tubal intraepithelial carcinoma in Chinese women.
Wang J, Wu H, Zhang Y, et al.
International journal of clinical and experimental pathology 2017; (10(8)):8222-8232.
PMID: 31966673 - 6
Ovarian cancer.
Matulonis UA, Sood AK, Fallowfield L, et al.
Nature reviews. Disease primers 2016; (2()):16061 doi:10.1038/nrdp.2016.61.
PMID: 27558151 - 7
Unveiling the Promise: A Comprehensive Review of Salpingectomy as a Vanguard for Ovarian Cancer Prevention.
Mundhada PV, Bakshi AM, Thtipalli N, Yelne S
Cureus 2024; (16(1)):e53088 doi:10.7759/cureus.53088.
PMID: 38414692 - 8
Prophylactic salpingectomy for prevention of ovarian cancer at the time of elective laparoscopic cholecystectomy.
Tomasch G, Lemmerer M, Oswald S, et al.
The British journal of surgery 2020; (107(5)):519-524 doi:10.1002/bjs.11419.
PMID: 32129898 - 9
No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.
Salvador S, Scott S, Francis JA, et al.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2017; (39(6)):480-493 doi:10.1016/j.jogc.2016.12.005.
PMID: 28527613 - 10
Salpingectomy to reduce risk of ovarian cancer in women at average risk.
Arruda J
Menopause (New York, N.Y.) 2019; (26(9)):1059-1061 doi:10.1097/GME.0000000000001407.
PMID: 31453970 - 11
Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: a cost-effectiveness analysis.
Adjei NN, Yeh PG, Haas A, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; (36(6)):102884 doi:10.1016/j.ijgc.2025.102884.
PMID: 41605705 - 12
Opportunistic salpingectomy in women undergoing hysterectomy: Results from the HYSTUB randomised controlled trial.
Van Lieshout LAM, Pijlman B, Vos MC, et al.
Maturitas 2018; (107()):1-6 doi:10.1016/j.maturitas.2017.09.012.
PMID: 29169572 - 13
Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada.
Hanley GE, Kwon JS, McAlpine JN, et al.
American journal of obstetrics and gynecology 2020; (223(2)):221.e1-221.e11 doi:10.1016/j.ajog.2020.02.005.
PMID: 32067967 - 14
Prophylactic Salpingectomy during Hysterectomy for Benign Disease: A Prospective Study to Evaluate High-Grade Serous Ovarian Carcinoma Precursors.
Tchartchian G, Bojahr B, Heils L, et al.
Journal of clinical medicine 2022; (12(1)) doi:10.3390/jcm12010296.
PMID: 36615096 - 15
Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?
Kotsopoulos J, Narod SA
International journal of cancer 2020; (147(5)):1245-1251 doi:10.1002/ijc.32916.
PMID: 32037528 - 16
Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?
Boerner T, Long Roche K
Journal of minimally invasive gynecology 2021; (28(3)):403-408 doi:10.1016/j.jmig.2020.09.020.
PMID: 33038519 - 17
Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
Harmsen MG, Piek JMJ, Bulten J, et al.
Cancer 2018; (124(5)):952-959 doi:10.1002/cncr.31211.
PMID: 29315498 - 18
Navigating dual risks: Ovarian cancer prevention and cardiovascular health in patients with hereditary cancer syndromes.
Keenahan L, Ahsan MD, Mecklai A, Frey MK
Gynecologic oncology reports 2025; (61()):101940 doi:10.1016/j.gore.2025.101940.
PMID: 41036493 - 19
Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
Johansen N, Liavaag AH, Iversen OE, et al.
Acta obstetricia et gynecologica Scandinavica 2017; (96(5)):547-555 doi:10.1111/aogs.13120.
PMID: 28236297 - 20
Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.
Lugo Santiago N, Smith E, Cox M, et al.
Obstetrics and gynecology 2020; (135(6)):1270-1274 doi:10.1097/AOG.0000000000003864.
PMID: 32459417 - 21
Screening and prevention of ovarian cancer.
Sideris M, Menon U, Manchanda R
The Medical journal of Australia 2024; (220(5)):264-274 doi:10.5694/mja2.52227.
PMID: 38353066 - 22
Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
Gaba F, Robbani S, Singh N, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021; (31(2)):286-291 doi:10.1136/ijgc-2020-001541.
PMID: 32907814 - 23
Global epidemiology of epithelial ovarian cancer.
Webb PM, Jordan SJ
Nature reviews. Clinical oncology 2024; (21(5)):389-400 doi:10.1038/s41571-024-00881-3.
PMID: 38548868
This page explains the role of fallopian tube removal in preventing ovarian cancer for educational purposes only. Always consult a gynecologic oncologist or genetic counselor to understand your personal risk and surgical options.
Get notified when new evidence is published on Ovarian Cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.